New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?

Date publication

novembre 2020

Journal

Current opinion in pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
D'Amico F, Peyrin-Biroulet L, Danese S, Fiorino G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33254032

Résumé

Over the past twenty years several biological drugs and the first small molecule have been approved for the treatment of patients with inflammatory bowel diseases (IBD). However, a large percentage of patients do not respond to therapies and the demand for new effective drugs is still an unmet need. The better understanding of the pathophysiological mechanisms of disease has allowed to identify new therapeutic targets to block inflammatory pathways. To date, many emerging drugs have been developed and are being tested for both ulcerative colitis and Crohn's disease patients. Here, we summarize the efficacy and safety data of the most promising drugs that could soon enrich the therapeutic armamentarium of IBD patients.

Référence

Curr Opin Pharmacol. 2020 Nov 27;55:141-150